Blockade of CTLA-4 results in autoimmune disease and colitis in normal mice (46, 47), exacerbates diabetes in diabetes-prone non-obese mice (48), and abrogates Treg cell-mediated suppression (47, 49). Here, CTLA4 is linked to colitis.